Phase 2, Multiple-Site, Randomized, Open Label Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

Condition:   Psychostimulant Drug Induced Toxicity Intervention:   Drug: Ryanodex (dantrolene sodium) for injectable suspension Sponsor:   Eagle Pharmaceuticals, Inc. Not yet recruiting - verified June 2017

Source: ClinicalTrials.gov - June 14, 2017 Category: Research Source Type: clinical trials